Pre-made Lerdelimumab benchmark antibody (Whole mAb, anti-TGFB2 therapeutic antibody, Anti-G-TSF/LDS4/TGF-beta2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-889

Anti-TGFB2 therapeutic antibody (Pre-made Lerdelimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-889-1mg 1mg 3090
GMP-Bios-INN-889-10mg 10mg Inquiry
GMP-Bios-INN-889-100mg 100mg Inquiry
GMP-Bios-INN-889-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Lerdelimumab Biosimilar, Whole Mab, Anti-Tgfb2 Antibody: Anti-G-TSF/LDS4/TGF-beta2 therapeutic antibody
INN Name Lerdelimumab
TargetTGFB2
FormatWhole mAb
Derivationhuman
Species Reactivityhuman
CH1 IsotypeIgG4 - nd
VD LCIgG4 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesCambridge Antibody Technology (Cambridge UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0